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Mast cell leukemia (MCL) is an extremely rare and aggres-
sive form of systemic mastocytosis (SM),1 accounting for 
<1% of all adult SM, with ≥20% atypical and immature mast 
cells (MC) in bone marrow. There are two known forms of 
presentation for MCL, the classic case in which MCs ac-
count for ≥10% of the peripheral white blood cells and the 
more frequent aleukemic variant with less than 10% MCs 
in peripheral blood. De novo MCL should be distinguished 
from secondary MCL, evolving from other advanced SM. 
Diagnostic criteria and classification of SM have been up-
dated in the 2017 World Health Organization classification.2 
Most cases of MCL have markedly high levels of serum 
tryptase, peripheral cytopenia, and/or leukocytosis with eo-
sinophilia. Patients can develop any of the typical clinical 
features of SM due to organ impairment or MC activation, 
although skin lesions are not usually detectable. Atypical 
MCs show an abnormal antigen expression, characteristically 
CD2 and/or CD25 with the expression of concurrent imma-
turity markers.1-3 Furthermore, most cases of aggressive SM 
harbor c‐Kit tyrosine kinase domain mutations, most fre-
quently D816V,4 without recurrent chromosomal aberrations 
detected to date.5 Therapeutic approaches are limited and, in 
general, prognosis of MCL is poor with less than one‐year 
survival in most patients.3
We report the case of an 86‐year‐old Caucasian male 
referred to the emergency care with upper gastrointestinal 
bleeding due to esophageal ulcers (LA grade D esophagitis), 
which were successfully treated by endoscopy and with a 
proton‐pump inhibitor, and concomitant severe acute throm-
bocytopenia, that prevented from taking a biopsy of the le-
sion. Initially, the thrombocytopenia was medically treated 
as immune‐mediated without response. In addition, grade 
2 normocytic anemia (Hb 80‐99  g/L) persisted in the fol-
lowing blood tests, with no renal or hepatic failure and nor-
mal lactate dehydrogenase, a normal leukocyte total count 
(5.1 × 109/L [3.8‐11.0]) with 71% neutrophil, 5% myelocyte, 
and 1% of atypical MCs and high levels of serum tryptase 
(501 µ/L [<15]).
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Abstract
We report a de novo aleukemic form of MCL with a complex monosomic karyo-
type with LOH for multiple chromosomes and TP53 mutation. Additionally, whereas 
D816V KIT was not found, the c‐Kit transmembrane domain p.M541L variant was 
detected which is the most common SNP of KIT gene in humans with controversial 
pathogenic role. In these cases, it is crucial to perform a rapid broad molecular study 
for an accurate diagnosis which could help to initiate targeted therapy.
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Bone marrow was diffusely infiltrated by 60% of large 
atypical cells with loose chromatin and centric and round 
nuclei, atypical mast cell type I (MC I), and occasionally 
even larger ones with polylobed nuclei (promastocytes or 
atypical MC II) distributed in multiple aggregates.6 Most of 
the atypical MCs exhibited a characteristic wide cytoplasm 
with azurophilic granules and multiple heavy inclusions or 
bizarre‐looking vacuoles, not stained with May‐Grünwald‐
Giemsa (MGG) (Figure 1A,B). Dysplastic features were 
absent in the peripheral blood and the bone marrow. These 
cells were positive for c‐Kit (CD117) and CD2 by immuno-
histochemical staining. Myeloperoxidase was negative, chlo-
roacetate esterase weakly positive, and toluidine blue stain 
revealed metachromatic granulated blast‐like cells (Figure 
1C,D). Electronic microscopy disclosed three distinct types 
of MCs (immature, mature, and activated MCs) characterized 
by its cytoplasmic granules which appear during their matu-
ration (Figure 1E‐G).
The immunophenotype of the neoplastic cells assessed 
by multiparametric flow cytometry was as follows: CD117, 
F I G U R E  1  (A‐F) Morphology and immunohistochemistry. A, BM infiltration by atypical MCs type I and type II (arrow). B, Amplified 
bilobed MC type II or promastocyte (arrow). C, c‐Kit (CD117) immunohistochemical staining. D, Toluidine blue staining showing metachromatic 
MCs (arrows). (E‐G) MCs ultrastructure at different maturation stages. E, Immature MC with irregular agranulated cytoplasm, mitochondria, and 
smooth ER. F, Mature MC with a lot of microvilli on cell surface and granules that vary in size, shape, and electron density. G, Activated MC 
granules clustered near to the exocytosis sites. H, Sanger sequencing of TP53 exon 8 revealed the presence of a G→A base change resulting in a 
missense mutation G266R. BM, bone marrow; ER, endoplasmic reticulum; GR, granule; MC, mast cell; MT, mitochondria; SG, secretory granule
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CD2, CD25, CD34, HLA‐DR, and CD123 were positive, 
whereas CD45, MPO, and TdT were negative.
Conventional cytogenetic studies revealed a com-
plex monosomic karyotype: 35,XY,‐1,‐3,‐5,add(5)(q32)
,‐7,‐10,‐11,‐12,‐13,‐15,‐16,‐17,‐18,+mar1[2]/35,XY,i(1)
(q10),‐3,‐5,add(5)(q32),‐7,‐10,‐11,‐12,‐13,‐15,‐16,‐17,‐18[
2]/46,XY[16] (Figure S1). DNA arrays performed with an 
Affymetrix platform and Cytoscan 750K confirmed these 
findings along with the detection of loss of heterozygosity 
regions (LOH) (Table 1A).
Mutation screening with conventional PCR techniques, 
as previously described, ruled out mutations in KIT D816V, 
FLT3, NPM1, CEBPA, MLL, IDH1, IDH2, as well as the re-
arrengements CBFB‐MYH11 and RUNX1‐RUNX1T1.
An amplicon‐based targeted next‐generation sequencing 
(NGS) myeloid panel of 42 genes (Haloplex TM, Agilent 
Technologies) routinely used in our institution based on 
published studies of Bullinger et al group detected a KIT 
M541L variant in exon 10 (transmembrane domain)7 and a 
TP53 missense pathogenic mutation that was confirmed by 
Sanger sequencing (Figure 1H). Other concurrent allelic 
variants of GATA2, EZH2, and ANKRD26 genes were de-
tected (Table 1B). All these variants have previously been 
described and reported as polymorphisms of uncertain patho-
genic significance.
Therefore, the patient was diagnosed with de novo aleu-
kemic MCL, according to the 2017 WHO criteria. Due to a 
rapid clinical deterioration, midostaurin was started, before 
obtaining the final molecular studies results. Despite this, the 
clinical status worsened and the patient died one month after 
diagnosis.
To sum up, we report an aleukemic form of MCL case 
with a complex monosomic karyotype. We also identified 
LOH regions of chromosomes 3, 5, 7, 9, and 10.8 Of note, 
our patient harbored a TP53 mutation which has already 
been defined as an early transforming event in hematologic 
malignancies.9 As it has been reported, our patient lacked 
the D816V KIT mutation; however, a c‐Kit transmembrane 
domain p.M541L variant was detected and it could modify 
the phenotype of a neoplastic myeloid progenitor trans-
formed by TP53 mutation. In fact, this KIT allelic vari-
ant in exon 10 is the most common SNP found in the KIT 
gene in humans and its pathogenic role is controversial.7 
The contributing effects of the other variants remain to be 
elucidated.5,10,11
Further MCL cases should be analyzed with the newly 
available techniques before drawing more precise conclu-
sions about the genomic landscape of this infrequent disease. 
In these cases, it is crucial to perform a rapid broad molecular 
study for an accurate diagnosis which could help to initiate 
targeted therapy.
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T A B L E  1  (A) List of LOH as determined using CytoScan 750K 
Array; (B) Allelic variants identified by NGS
A
Chrom. Cytoband/Location Start (Mb)a End (Mb)a
3 3p21.31‐p21.2 47 002 139 50 797 870
5 5q34‐q35.2 167 244 759 176 110 659
7 7p21.2‐p15.3 14 753 209 22 086 697
7 7q11.21 62 569 501 66 530 404
7 7q31.31 117 485 006 120 694 229
9 9q31.1‐q31.2 107 580 656 111 256 573
10 10q22.1‐q22.2 73 731 650 77 131 019
B
Gene AA variant cDNA variant VAF
KIT p.M541L c.1621A>C 0.57
TP53 p.G266R c.796G>A 0.075
GATA2 p.A164T c.490G>A 0.54
EZH2 p.D185H c.553G>A 0.48
ANKRD26 p.Q20R c.59A>G 0.56
Abbreviations: AA, aminoacid; Chrom, chromosome; VAF, variant allele 
frequency.
aNucleotide position of the origin and the end of the aberration in the reference 
genome (hg19). 
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